Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre‐specified subgroup with heart failure

AIMS: The AMBER trial demonstrated that concomitant use of patiromer enabled the more persistent use of spironolactone by reducing the risk of hyperkalaemia in patients with resistant hypertension and advanced chronic kidney disease. We report herein the pre‐specified subgroup analysis in patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossignol, Patrick, Williams, Bryan, Mayo, Martha R., Warren, Suzette, Arthur, Susan, Ackourey, Gail, White, William B., Agarwal, Rajiv
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd. 2020
Materias:
TREATMENT
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540031/
https://www.ncbi.nlm.nih.gov/pubmed/32452085
http://dx.doi.org/10.1002/ejhf.1860

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540031/
https://www.ncbi.nlm.nih.gov/pubmed/32452085
http://dx.doi.org/10.1002/ejhf.1860

Ejemplares similares